Oric Pharmaceuticals
Dominic Piscitelli possesses extensive experience in financial leadership and board governance within the biotechnology and pharmaceutical sectors. Currently serving as the Chief Financial Officer at ORIC Pharmaceuticals and as an Independent Board Member and Audit Committee Chair at Alterome Therapeutics, Dominic has also held pivotal roles including Board Member at Celyad and Chief Financial Officer at AnaptysBio. Previous experience includes senior finance positions at Medivation and Astellas Pharma, as well as an Audit Manager role at KPMG. Dominic holds a Master’s degree in Accounting and Finance from Hofstra University, where undergraduate studies were also completed.
This person is not in any offices
Oric Pharmaceuticals
ORIC Pharmaceuticals is a privately held, clinical-stage oncology company focused on making cancer treatments more effective by addressing mechanisms of resistance. ORIC's lead asset, ORIC-101, is a potent and selective small-molecule antagonist of the glucocorticoid receptor. ORIC's pipeline targets other undisclosed mechanisms of oncology therapy resistance. ORIC's scientific founders are Drs. Charles Sawyers, MD, and Scott Lowe, PhD, who have strong records of discovering innovative treatments and targets in cancer. The company has assembled strong leadership and scientific teams and a board with extensive experience in drug development and financing. ORIC is funded by leading biotechnology investors, including The Column Group, Topspin Partners, OrbiMed Advisors, EcoR1 Capital, Fidelity Management & Research Company, Trinitas Capital, Foresite Capital, Taiho Ventures, Memorial Sloan Kettering, Kravis Investment Partners, NS Investment and City Hill Ventures. ORIC is headquartered in South San Francisco, California.